Paul A. Friedman
CIK: 0001236927
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (89 total)
- Jun 9, 2026PRLD
Prelude Therapeutics Inc
Award(A)DirectDirector Stock Option (Right to Buy)
38K shares- - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Exercise(M)Direct280 shares at avg. $15.80$4K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct280 shares at avg. $551.24$154K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct1.5K shares at avg. $511.98$758K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct1.4K shares at avg. $518.68$707K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct1.1K shares at avg. $513.11$561K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Exercise(M)Direct24.5K shares at avg. $15.80$387K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct2K shares at avg. $515.81$1.0M - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct766 shares at avg. $516.84$396K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct2.5K shares at avg. $517.86$1.3M - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct280 shares at avg. $530.69$149K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct846 shares at avg. $519.88$440K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct681 shares at avg. $521.03$355K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct840 shares at avg. $521.98$438K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $524.10$628K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct970 shares at avg. $523.00$507K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct2.4K shares at avg. $525.05$1.3M - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct1.1K shares at avg. $526.00$561K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct1.6K shares at avg. $526.97$822K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct575 shares at avg. $528.18$304K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct691 shares at avg. $529.17$366K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct166 shares at avg. $529.76$88K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct1.3K shares at avg. $514.68$692K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct80 shares at avg. $532.50$43K - Jan 9, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct332 shares at avg. $534.16$177K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 9, 2026 |  PRLD Prelude Therapeutics Inc | Award(A) Director Stock Option (Right to Buy) | 38,000 | - | - | Direct |
| Jan 9, 2026 |  MDGL MADRIGAL PHARMACEUTICALS, INC. | Exercise(M) | 280 | $15.80 | $4,424 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 280 | $551.24 | $154,348 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 1,480 | $511.98 | $757,727 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 1,363 | $518.68 | $706,966 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 1,094 | $513.11 | $561,340 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Exercise(M) | 24,520 | $15.80 | $387,416 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 1,996 | $515.81 | $1,029,561 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 766 | $516.84 | $395,896 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 2,450 | $517.86 | $1,268,755 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 280 | $530.69 | $148,592 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 846 | $519.88 | $439,822 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 681 | $521.03 | $354,823 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 840 | $521.98 | $438,461 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 1,199 | $524.10 | $628,394 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 970 | $523.00 | $507,307 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 2,432 | $525.05 | $1,276,916 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 1,066 | $526.00 | $560,717 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 1,560 | $526.97 | $822,071 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 575 | $528.18 | $303,702 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 691 | $529.17 | $365,653 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 166 | $529.76 | $87,941 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 1,345 | $514.68 | $692,246 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 80 | $532.50 | $42,600 | Direct |
| Jan 9, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 332 | $534.16 | $177,342 | Direct |
1-25 of 89 transactions
About FRIEDMAN PAUL A
FRIEDMAN PAUL A (SEC CIK 0001236927) files insider reports with the SEC as Director of Prelude Therapeutics Inc (PRLD) and Director of MADRIGAL PHARMACEUTICALS, INC. (MDGL).
Signal8 holds 10 ownership filings by FRIEDMAN PAUL A, all Form 4s, filed between Jun 13, 2025 and Jun 10, 2026. Those filings report 89 transactions, from Jun 12, 2025 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on FRIEDMAN PAUL A's filings is in WILMINGTON, DE.
Recent filings by FRIEDMAN PAUL A
- Jun 9, 2026: Grant or award of PRLD derivative securities (Form 4, code A).
- Jan 9, 2026: Option exercise of MDGL shares (Form 4, code M).
- Jan 9, 2026: Open-market sales of MDGL shares (4 lines, Form 4, code S).
- Jan 9, 2026: Option exercise of MDGL shares (Form 4, code M).
- Jan 9, 2026: Open-market sales of MDGL shares (18 lines, Form 4, code S).
Other insiders filing for Prelude Therapeutics Inc (PRLD)
- BAKER BROS. ADVISORS LP, Director
- Dorton Katina, Director
- Babler Martin, Director
- Bonita David P, Director
- Sandor Victor, Director
- Morris Charles Q, Chief Medical Officer